Cargando…
Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern
The development of safe and effective new drug treatments for schizophrenia poses a challenging task. This class of drugs is known to be associated with a wide range of serious and troublesome safety problems that include neurological, cardiac, endocrine, and metabolic side effects. Many of these dr...
Autor principal: | Shah, Rashmi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181691/ https://www.ncbi.nlm.nih.gov/pubmed/22033499 |
Ejemplares similares
-
Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation
por: Lerer, Bernard, et al.
Publicado: (2006) -
The impact of subjective well-being under neuroleptic treatment on compliance and remission
por: de Millas, Walter, et al.
Publicado: (2006) -
Application of a Pharmacogenetics-Based Precision Medicine Model (5SPM) to Psychotic Patients That Presented Poor Response to Neuroleptic Therapy
por: Carrascal-Laso, Lorena, et al.
Publicado: (2020) -
Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam
por: Yacoub, Adeeb, et al.
Publicado: (2006) -
Neuroleptic Malignant Syndrome Improved with Intramuscular Administration of the Anticholinergic Agent, Biperiden
por: Nisijima, Koichi
Publicado: (2023)